

## REFERENCES

1. Pharmaceutical Research and Manufacturers of America. [Internet.] 2007 Report. Medicines in development for heart disease and stroke. Available at <http://www.phrma.org/files/Heart%202007.pdf>
2. U.S. National Institutes of Health. [Internet.] ClinicalTrials.gov. Search. Available at <http://clinicaltrials.gov/ct2/home>
3. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain: a meta-analysis. *JAMA* 1995; 274: 975-80.
4. Wind J, Koelemay MJ. Exercise therapy and the additional effect of supervision on exercise therapy in patients with intermittent claudication. Systematic review of randomised controlled trials. *Eur J Vasc Endovasc Surg* 2007; 34(1): 1-9.
5. Thompson PD, Zimet R, Forbes WP, Zhang P. meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. *AM J Cardiol* 2002; 90: 1314-19.
6. Hiatt WR, Cox L, Greenwalt M, et al. Quality of the assessment of primary and secondary endpoints in claudication and critical limb ischemia trials. *Vasc Med* 2005; 10: 207-13.
7. Abbenante G, Fairlie DP. Protease inhibitors in the clinic. *Med Chem* 2005; 1: 71-104.
8. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. *Circ Res* 2007; 100: 1261-75.
9. Steinhubl SR, Schneider DJ, Berger PB, Becker RC. Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials. *J Thromb Thrombolysis* 2007; Epub 2007 Nov 1.
10. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors. Recognition of a two-edged sword? *Circulation* 2002; 106: 379-85.
11. Topol EJ, Easton D, Harrington RA, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. *Circulation* 2003; 108: 399-406.
12. Schneider DJ, Sobel BE. Conundrums in the combined use of anticoagulants and antiplatelet drugs. *Circulation* 2007; 116: 305-15.
13. Emmerich J. Current state and perspective on medical treatment of critical limb ischemia: gene and cell therapy. *Int J Low Extrem Wounds* 2005; 4(4): 234-41.

14. Yla-Herttuala S, Alitalo K. Gene transfer as a tool to induce vascular growth. *Nat Med* 2003; 9(6): 694-701.
15. Spies C, Snell J. [Internet]. Therapeutic angiogenesis for treatment of PAD. Critical Limb Ischemia Council. [Cited 2007 Dec.] Available at [http://cli-council.com/readarticle.php?article\\_id=5](http://cli-council.com/readarticle.php?article_id=5)
16. Webster KA, Spiga, M, Wilson AA, et al. [Internet.] Combination cell and gene therapy for peripheral ischemia using myoblasts and stem cells engineered with conditionally silenced genes. *Molecular and Cellular Pharmacology, Vascular Biology Institute, University of Miami School of Medicine, Miami, FL* [Cited 2007 Dec.] Available at <http://www.med.miami.edu/mnbws/documents/06SpeakerWebster.pdf>
17. Aviles RJ, Annex BH, Lederman RJ. Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2). *Br J Pharm* 2003; 140: 637-46.
18. Grossman PM, Mendelsohn F, Henry T, et al. Results from a phase II multicenter, double blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. *Am Heart J* 2007; 153(3): 874-80. Abstract.
19. Van Royen N, Schirmer SH, Atasever B, et al. START Trial. A pilot study on stimulation of arteriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease. *Circulation* 2005; 112: 1040-46.